UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.146-156

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

Targeted oncology, 2022-01, Vol.17 (1), p.25-33

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

JTO clinical and research reports, 2021-03, Vol.2 (3), p.100136-100136, Article 100136

2021

Link zum Volltext

Verfügbarkeit prüfen

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

JTO clinical and research reports, 2022-10, Vol.3 (10), p.100406-100406, Article 100406

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17598-e17598

2023

Link zum Volltext

Verfügbarkeit prüfen

PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17601-e17601

2023

Link zum Volltext

Verfügbarkeit prüfen

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

Cancer science, 2023-06, Vol.114 (6), p.2524-2533

2023

Link zum Volltext

Verfügbarkeit prüfen

Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Value in health, 2023-01, Vol.26 (1), p.64-70

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

The lancet respiratory medicine, 2023-04, Vol.11 (4), p.354-366

2023

Link zum Volltext

Verfügbarkeit prüfen

MO9-1 Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan

Annals of oncology, 2021-07, Vol.32, p.S300-S300

2021

Link zum Volltext

Verfügbarkeit prüfen

The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults

Journal of multidisciplinary healthcare, 2017-01, Vol.10, p.437-444

2017

Link zum Volltext

Verfügbarkeit prüfen

Ensuring relevance and equity in patient reported outcomes (PROs) in gynecologic malignancy: The PROMOTE study (Patient-reported Outcomes Measurement Opportunities Through Equity) (1324)

Gynecologic oncology, 2023-09, Vol.176, p.S197-S197

2023

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data

Future oncology (London, England), 2022-06, Vol.18 (17), p.2063-2074

2022

Link zum Volltext

Verfügbarkeit prüfen

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden

Applied health economics and health policy, 2023-07, Vol.21 (4), p.661-672

2023

Link zum Volltext

Verfügbarkeit prüfen

Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience

Gynecologic oncology reports, 2024-08, Vol.54, p.101440, Article 101440

2024

Link zum Volltext

Verfügbarkeit prüfen

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

PharmacoEconomics, 2021-08, Vol.39 (8), p.941-952

2021

Link zum Volltext

Verfügbarkeit prüfen

Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)

Future oncology (London, England), 2021-10, Vol.17 (30), p.3951-3964

2021

Link zum Volltext

Verfügbarkeit prüfen

The burden of selected cancers in the US: health behaviors and health care resource utilization

Cancer management and research, 2017-01, Vol.9, p.721-730

2017

Link zum Volltext

Verfügbarkeit prüfen

P3-26-75 (C). Crizotinib use in Japanese patients tested for ROS1 Non-small Cell Lung Cancer in real-world

Japanese Journal of Lung Cancer, 2020-10, Vol.60 (6), p.767-767

2020

Link zum Volltext

Verfügbarkeit prüfen

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Future oncology (London, England), 2023-05, Vol.19 (14), p.961-973

2023

Link zum Volltext

Verfügbarkeit prüfen

EN1-2. Ph3 CROWN study of 1L lorlatinib vs crizotinib in advanced ALK+ NSCLC : updated efficacy and safety

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.557-557

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT223-CT223

2022

Link zum Volltext

Verfügbarkeit prüfen

On the Clinical Importance of Benign Breast Disease: Causal Intermediary or Susceptibility Marker?

Iadeluca, Laura Reimers

2015

Link zum Volltext
ProQuest

Nuclear medicine in primary bone tumors

European journal of radiology, 1998-05, Vol.27 (Suppl. 1), p.S123-S131

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(22)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Oncology
(12)
Humans
(9)
Original
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Neoplasms - Drug Therapy
(5)
Cancer
(4)
Crizotinib
(4)
Crizotinib - Therapeutic Use
(4)
Health Care Sciences & Services
(4)
Lung Cancer
(4)
Protein Kinase Inhibitors - Therapeutic Use
(4)
Quality Of Life
(4)
Respiratory System
(4)
Adult
(3)
Business & Economics
(3)
Economics
(3)
Epidemiology
(3)
Health Policy & Services
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer

PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

MO9-1 Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan

The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults

Ensuring relevance and equity in patient reported outcomes (PROs) in gynecologic malignancy: The PROMOTE study (Patient-reported Outcomes Measurement Opportunities Through Equity) (1324)

Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden

Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)

The burden of selected cancers in the US: health behaviors and health care resource utilization

P3-26-75 (C). Crizotinib use in Japanese patients tested for ROS1 Non-small Cell Lung Cancer in real-world

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

EN1-2. Ph3 CROWN study of 1L lorlatinib vs crizotinib in advanced ALK+ NSCLC : updated efficacy and safety

Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

On the Clinical Importance of Benign Breast Disease: Causal Intermediary or Susceptibility Marker?

Nuclear medicine in primary bone tumors

Suchergebnisse filtern